With only a few hours of trade left before today's closing bell, the S&P/ASX 200 Index (ASX: XJO) is up 0.9% since last Friday's close, with these three surging ASX 200 stocks leaving those gains in the dust.
Here's what's been catching ASX investor interest this week.
Image source: Getty Images
Genesis Minerals Ltd (ASX: GMD)
Genesis Minerals shares closed last Friday trading for $5.39. At the time of writing, shares are swapping hands for $6.18 apiece. That sees this ASX 200 stock up 14.7% for the week.
Most of those gains are being delivered today after the Aussie gold miner released a business update.
Investors reacted positively to the miner reporting that its FY 2026 gold production hit 285,400 ounces. That's towards the higher end of Genesis Minerals' full-year guidance of 260,000 ounces to 290,000 ounces.
On the cost front, the gold mine also reported its full-year all-in sustaining cost (AISC) came within its FY 2026 guidance range of $2,500 to $2,700 per ounce.
And the balance sheet is growing, with Genesis Minerals reporting underlying cash and equivalents of $258 million, up from $253 million in March.
Perpetual Ltd (ASX: PPT)
The second ASX 200 stock shooting the lights out this week is financial services company Perpetual.
Perpetual shares closed last Friday at $15.19 and are currently trading at $19.12. This sees the Perpetual share price up 25.9% over the week.
Perpetual shares leapt 16.8% on Wednesday after the company announced that it had received, and rejected, an unsolicited, non-binding takeover proposal from Windflower. According to the release, Windflower is indirectly controlled by EQT AB.
Under the terms of the indicative proposal, Perpetual shareholders would have received $21.64 per share in cash, or almost 40% above Tuesday's closing price.
In explaining its rejection, the Perpetual board noted:
The indicative proposal was highly conditional and did not adequately represent fair value for Perpetual shareholders in the context of a change of control transaction and the board determined that it was not in the best interests of Perpetual shareholders.
Which brings us to…
Neuren Pharmaceuticals Ltd (ASX: NEU)
The top-performing ASX 200 stock on my list today is Neuren Pharmaceuticals.
Shares in the biopharmaceutical company closed last Friday trading for $12.20. At the time of writing, shares are changing hands for $16.71 each. This sees the Neuren share price up 37% for the week.
Neuren shares closed up a whopping 36.1% on Monday after announcing a crucial regulatory win in the European Union (EU) for its lead drug, DAYBUE.
DAYBUE is intended to treat neurobehavioral symptoms of Rett syndrome.
Commenting on the positive decision from the Committee for Medicinal Products for Human Use (CHMP), Neuren CEO Jon Pilcher said, "I am so delighted for all stakeholders to see this positive outcome from the CHMP re-examination process recommending marketing authorisation for DAYBU in the EU."
